Treatment Options for Pancreatic Neuroendocrine Tumors

被引:51
作者
Akirov, Amit [1 ,2 ,3 ]
Larouche, Vincent [3 ,4 ]
Alshehri, Sameerah [3 ]
Asa, Sylvia L. [5 ]
Ezzat, Shereen [3 ]
机构
[1] Beilinson Med Ctr, Inst Endocrinol, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[3] Princess Margaret Canc Ctr, Dept Endocrine Oncol, Toronto, ON M5G 1Z5, Canada
[4] McGill Univ, Jewish Gen Hosp, Dept Med, Div Endocrinol & Metab, Montreal, PQ H3T 1E2, Canada
[5] Univ Hlth Network, Univ Toronto, Dept Pathol, Toronto, ON M5S 1A1, Canada
关键词
neuroendocrine tumors; pancreas; pancreatic cancer; ENETS CONSENSUS GUIDELINES; LIVER-METASTASES; DEPOT OCTREOTIDE; SUNITINIB MALATE; BEVACIZUMAB; EVEROLIMUS; TRIAL; MANAGEMENT; UPDATE; LU-177-DOTATATE;
D O I
10.3390/cancers11060828
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy.
引用
收藏
页数:13
相关论文
共 44 条
  • [1] Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation
    Bartolini, Ilenia
    Bencini, Lapo
    Risaliti, Matteo
    Ringressi, Maria Novella
    Moraldi, Luca
    Taddei, Antonio
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2018, 2018
  • [2] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
    Brabander, Tessa
    van der Zwan, Wouter A.
    Teunissen, Jaap J. M.
    Kam, Boen L. R.
    Feelders, Richard A.
    de Herder, Wouter W.
    van Eijck, Casper H. J.
    Franssen, Gaston J. H.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4617 - 4624
  • [3] External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review
    Chan, D. L.
    Thompson, R.
    Lam, M.
    Pavlakis, N.
    Hallet, J.
    Law, C.
    Singh, S.
    Myrehaug, S.
    [J]. CLINICAL ONCOLOGY, 2018, 30 (07) : 400 - 408
  • [4] Chen JP, 2013, EXPERT REV ANTICANC, V13, P737, DOI [10.1586/ERA.13.45, 10.1586/era.13.45]
  • [5] Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
    Costa, Ricardo
    Costa, Rubens
    Bacchi, Carlos E.
    Almeida Filho, Paulo
    [J]. CASE REPORTS IN ENDOCRINOLOGY, 2013, 2013
  • [6] Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors
    Crippa, Stefano
    Partelli, Stefano
    Zamboni, Giuseppe
    Scarpa, Aldo
    Tamburrino, Domenico
    Bassi, Claudio
    Pederzoli, Paolo
    Falconi, Massimo
    [J]. SURGERY, 2014, 155 (01) : 145 - 153
  • [7] Sunitinib achieved fast and sustained control of VIPoma symptoms
    de Mestier, Louis
    Walter, Thomas
    Brixi, Hedia
    Lombard-Bohas, Catherine
    Cadiot, Guillaume
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (01) : K1 - K3
  • [8] Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
    Ducreux, Michel
    Dahan, Laetitia
    Smith, Denis
    O'Toole, Dermot
    Lepere, Celine
    Dromain, Clarisse
    Vilgrain, Valerie
    Baudin, Eric
    Lombard-Bohas, Catherine
    Scoazec, Jean-Yves
    Seitz, Jean-Francois
    Bitoun, Laurence
    Kone, Sebastien
    Mitry, Emmanuel
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3098 - 3106
  • [9] Dumont RA, 2015, AM J NUCL MED MOLEC, V5, P46
  • [10] ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
    Falconi, M.
    Eriksson, B.
    Kaltsas, G.
    Bartsch, D. K.
    Capdevila, J.
    Caplin, M.
    Kos-Kudla, B.
    Kwekkeboom, D.
    Rindi, G.
    Kloeppel, G.
    Reed, N.
    Kianmanesh, R.
    Jensen, R. T.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 (02) : 153 - 171